Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.61 |
| ▸ | MEN1 | O00255 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | HTT | P42858 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | XBP1 | P17861 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12491436 | 0.88 | MTOR (0.57) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL59228 | 0.87 | KDR (0.53) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL59095 | 0.87 | KDR (0.53) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL59458 | 0.87 | KMT2A (0.66) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL60251 | 0.86 | KMT2A (0.53) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL59103 | 0.86 | KDR (0.60) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL59298 | 0.85 | KMT2A (0.54) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL22915771 | 0.85 | MEN1 (0.54) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL25272009 | 0.85 | LMNA (0.61) | KMT2AMEN1MAPTHTTRAB9A | |
| SCHEMBL3185068 | 0.84 | MAPT (0.61) | KMT2AMEN1MAPTHTTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-03-28 | — | — | US | disclosed |
| US-20210155626-A1 | MODULATION OF IRE1 | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION | 2021-05-27 | — | — | US | disclosed |
| US-10822340-B2 | Substituted imidazolopyrazine compounds and methods of using same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-03 | — | — | US | disclosed |
| US-20190084989-A1 | MODULATION OF IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2019-03-21 | — | — | US | disclosed |
| US-10131668-B2 | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-20 | — | — | US | disclosed |
| US-20170165259-A1 | COMBINED MODULATION OF IRE1 | NIH-DEITR | 2017-06-15 | — | — | US | disclosed |
| US-20160024094-A1 | MODULATION OF IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-01-28 | — | — | US | disclosed |
| WO-2016004254-A1 | COMBINED MODULATION OF IRE1 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-01-07 | — | — | WO | disclosed |
| EP-2900673-A1 | MODULATION OF IRE1 | The Regents of The University of California (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8940778-B2 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-1674469-A1 | Sulfonamido-macrocycles as Tie2 inhibitors | Schering Aktiengesellschaft (DE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1648905-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2006-04-26 | — | — | EP | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBVIE INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2005010009-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2005-02-03 | — | — | WO | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-01-27 | — | — | US | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABBOTT LABORATORIES | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084989-A1 | MODULATION OF IRE1 | XBP1, HSPA5, ERN2 | KMT2A 4125/4885MEN1 4620/4885MAPT 3283/4885 |
| US-10131668-B2 | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 | XBP1, HSPA5, ERN2 | KMT2A 3978/4885MEN1 4735/4885MAPT 3407/4885 |
| US-10822340-B2 | Substituted imidazolopyrazine compounds and methods of using same | HSPA5, XBP1, ERN2 | KMT2A 4296/4885MEN1 4699/4885MAPT 3710/4885 |
| US-20050020619-A1 | Thienopyridine kinase inhibitors | ABL1, MAP4K2, MAP4K5 | KMT2A 1067/4885MEN1 2198/4885MAPT 1332/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | KMT2A 1422/4885MEN1 2549/4885MAPT 1484/4885 |
| US-11613544-B2 | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 | XBP1, HSPA5, ATF4 | KMT2A 4106/4885MEN1 4740/4885MAPT 3896/4885 |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KMT2A 1305/4885MEN1 2197/4885MAPT 2008/4885 |
| US-20210155626-A1 | MODULATION OF IRE1 | XBP1, HSPA5, ERN2 | KMT2A 4125/4885MEN1 4620/4885MAPT 3283/4885 |
| US-20170165259-A1 | COMBINED MODULATION OF IRE1 | ERN2, ERN1, XBP1 | KMT2A 3784/4885MEN1 4417/4885MAPT 3165/4885 |
| US-20040235892-A1 | Indazole and benzisoxazole kinase inhibitors | ABL1, MAP3K19, MAP3K1 | KMT2A 1561/4885MEN1 2321/4885MAPT 3170/4885 |
| US-20160024094-A1 | MODULATION OF IRE1 | XBP1, HSPA5, ERN2 | KMT2A 4125/4885MEN1 4620/4885MAPT 3283/4885 |
| US-20050043347-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | KMT2A 1305/4885MEN1 2197/4885MAPT 2008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.